Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration

Overview of attention for article published in Frontiers in immunology, July 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

blogs: 1 blog

twitter: 25 X users

Citations

dimensions_citation: 16 Dimensions

Readers on

mendeley: 30 Mendeley

Summary Blogs X Dimensions citations

So far, Altmetric has seen 26 X posts from 25 X users, with an upper bound of 99,599 followers.

RT @Brandon_Beaber: Kesimpta vs. Ocrevus. Does it matter if you take your b-cell depleter IV or subcutaneously? Probably not. This study…

17 Aug 2022

Reply Repost Favourite

Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration https://t.co/3RdmQabFvt

16 Aug 2022

Reply Repost Favourite

RT @Brandon_Beaber: Kesimpta vs. Ocrevus. Does it matter if you take your b-cell depleter IV or subcutaneously? Probably not. This study…

16 Aug 2022

Reply Repost Favourite

RT @Brandon_Beaber: Kesimpta vs. Ocrevus. Does it matter if you take your b-cell depleter IV or subcutaneously? Probably not. This study…

16 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 22 additional X posts.